Article
Biochemistry & Molecular Biology
Gang Li, Shijie Xu, Ung Gu Kang
Summary: Repeated administration of drugs of abuse leads to behavioral sensitization, which is also observed with MK-801, a NMDA receptor antagonist. This study investigated the characteristics of MK-801-induced behavioral sensitization and found that it occurred rapidly with only five consecutive treatments. The optimal dose for sensitization was identified, which corresponded to typical doses of abused NMDA antagonists. Changes were observed in the expression and phosphorylation of NMDA receptor subunits after MK-801-induced behavioral sensitization.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Neurosciences
Wenjuan Yu, Hongwei Fang, Lei Zhang, Miaowen Hu, Sidi He, Huafang Li, Hao Zhu
Summary: Treatment with MK-801 enhances proliferation of hippocampal astrocytes and upregulates BDNF mRNA expression. The NMDA, PI3K, and ERK1/2 signaling pathways may be involved in regulating MK-801-induced BDNF upregulation. These findings suggest that astrocytes may play a role in the acute neurological and behavioral response to MK-801 treatment.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2021)
Article
Psychiatry
Tsung-Yu Pan, Yi-Ju Pan, Shih-Jen Tsai, Che-Wen Tsai, Feng-Yi Yang
Summary: This study investigated the efficacy of low-intensity pulsed ultrasound (LIPUS) in treating psychiatric symptoms and anxiety-like behaviors. The results showed that LIPUS stimulation improved deficits in locomotor activity and sensorimotor gating, improved anxiety-like behavior, and modulated the activity of NMDA receptors and c-Fos. Therefore, LIPUS may be a potentially valuable antipsychotic treatment for schizophrenia.
SCHIZOPHRENIA BULLETIN
(2023)
Article
Neurosciences
Ying Peng, Dong Xu, Yuedi Ding, Xingqin Zhou
Summary: This study found that dietary supplementation of PQQ from pregnancy or postpartum could effectively prevent schizophrenia-like behaviors in mice induced by MK-801. Female mice responded better to PQQ supplementation than males. In vitro experiments showed that early supplementation of PQQ promoted neuronal growth and neurite development.
PSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
James J. Gattuso, Carey Wilson, Anthony J. Hannan, Thibault Renoir
Summary: This study used the Sapap3 KO mouse model to investigate the pathology and potential novel pharmacological therapies for OCD. The results showed that the Sapap3 KO mice exhibited anxious, compulsive grooming, hypolocomotive, and reduced body weight phenotypes, but acute administration of ketamine did not reduce anxiety or grooming behavior. In addition, the study found evidence of altered functional NMDAR activity in Sapap3 KO mice, suggesting in vivo glutamatergic dysfunction.
Article
Psychiatry
Hagar Bauminger, Hiba Zaidan, Irit Akirav, Inna Gaisler-Salomon
Summary: NMDA receptor blockade in rodents can induce schizophrenia-like behavioral abnormalities, and the endocannabinoid system can modulate these abnormalities. The study shows that anandamide hydrolysis inhibitor can reverse the behavioral deficits induced by NMDA receptor blocker in adolescence. It also suggests that endocannabinoid stimulation may have therapeutic potential in treating treatment-resistant symptoms.
SCHIZOPHRENIA BULLETIN
(2022)
Article
Neurosciences
Zheng-yu Sun, Li-hong Gu, Deng-lei Ma, Ming-yang Wang, Cui-cui Yang, Lan Zhang, Xin-min Li, Jie-wen Zhang, Lin Li
Summary: The novel mouse model induced by the combination of CPZ and MK-801 exhibited severe spatial and recognition memory deficits, hyperactivity, and anxiety disorder. The mice showed obvious demyelination and white matter damage, along with decreased expression levels of myelin basic protein (MBP) and 2',3'-cyclic nucleotide-3'-phosphodiesterase (CNPase) in the corpus callosum. Additionally, phosphorylation levels of Fyn and NMDA receptors were noticeably decreased in specific brain regions.
BRAIN RESEARCH BULLETIN
(2021)
Article
Nutrition & Dietetics
Jia-Quan Liang, Xi Chen, Yong Cheng
Summary: The study demonstrates that paeoniflorin can alleviate schizophrenia-like behaviors through inhibiting the oxidative stress pathway. The potential mechanisms of restoring neuronal expression and preventing neurotoxicity were also revealed.
FRONTIERS IN NUTRITION
(2022)
Article
Agriculture, Multidisciplinary
Qiufang Zong, Kaiqi Li, Huan Qu, Ping Hu, Chao Xu, Haifei Wang, Shenglong Wu, Shuai Wang, Hao-Yu Liu, Demin Cai, Wenbin Bao
Summary: This research investigates the potential mechanism of sodium butyrate (NaBu) in modulating hepatic anti-oxidation and anti-inflammation pathways in deoxynivalenol (DON)-exposed piglets. The findings suggest that NaBu effectively reverses the liver injury, mononuclear cell infiltration, and decreased serum protein concentrations caused by DON, possibly through NR4A2-mediated histone acetylation. This highlights the potential of NaBu as a natural antimycotic additive in mitigating hepatic oxidative stress and inflammatory responses.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
(2023)
Article
Environmental Sciences
Murat Sirri Akosman, Ruhi Turkmen, Hasan Huseyin Demirel
Summary: The study demonstrated that resveratrol has a protective effect against glial cell infiltration and shrinkage of nerve cell nuclei induced by MK-801 in the brain. However, it did not correct behavioral disorders and demyelination of schizophrenia. Resveratrol partially prevented oxidative damage but not significantly.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2021)
Article
Clinical Neurology
Ian Masse, Luc Moquin, Caroline Bouchard, Alain Gratton, Louis De Beaumont
Summary: In this study, the effectiveness of prophylactic versus therapeutic administration of MK-801, an NMDA receptor antagonist, on the acute changes in amino acid extracellular concentrations resulting from a concussion was investigated. The results suggest that prophylactic administration of MK-801 significantly inhibits the immediate and indiscriminate release of glutamate, taurine, and glycine after a concussion.
JOURNAL OF NEUROSURGERY
(2022)
Article
Pharmacology & Pharmacy
Haikang Zhou, Guoqing Li, Yang Wang, Rendong Jiang, Yicheng Li, Huhu Wang, Fei Wang, Hairong Ma, Li Cao
Summary: This study investigated the chondroprotective properties of NaB in inflammatory chondrocyte models and ACLT mouse models, revealing that NaB attenuated cartilage degradation by promoting autophagy to inhibit inflammation, oxidative stress, and apoptosis, thus reducing extracellular matrix degradation. The protective effects of NaB against OA were partially mediated by enhancing autophagy through the PI3K/Akt/mTOR pathway both in vitro and in vivo, suggesting NaB as a potential novel therapeutic approach for OA.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Dongwoo Yu, Seul Ah Mun, Sang Woo Kim, Dae-Chul Cho, Chi Heon Kim, Inbo Han, Subum Lee, Sang -Woo Lee, Kyoung-Tae Kim
Summary: D-serine exacerbates neuropathic pain after traumatic spinal cord injury by mediating the NMDA receptor. NMDA receptor antagonists alleviate neuropathic pain after traumatic spinal cord injury.
Article
Biochemistry & Molecular Biology
Thiago C. Moulin, Tijana Stojanovic, Rasika P. Rajesh, Tirusha Pareek, Laura Donzelli, Michael J. Williams, Helgi B. Schioth
Summary: In this study, the effects of MK-801 on locomotion, sleep, and negative geotaxis in fruit flies were investigated. The results showed that MK-801 enhanced negative geotaxis activity and increased locomotion in a dose-dependent manner in acute administration. However, it did not affect sleep duration. This study provides further evidence for the functional conservation of the NMDA receptor system in flies and suggests the usefulness of the fruit fly model in investigating various phenotypes as an alternative to rodent models in drug discovery.
Article
Neurosciences
Leah Waldman, Brittany Richardson, John Hamilton, Panayotis Thanos
Summary: Olanzapine treatment significantly decreases NMDAR expression in certain brain regions, while haloperidol treatment and a high-fat diet have no effect on NMDAR expression.
NEUROSCIENCE LETTERS
(2022)
Review
Pharmacology & Pharmacy
Stephen I. Deutsch, Jessica A. Burket, Maria R. Urbano, Andrew D. Benson
BIOCHEMICAL PHARMACOLOGY
(2015)
Article
Clinical Neurology
Jessica A. Burket, Andrew D. Benson, Amy H. Tang, Stephen I. Deutsch
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2015)
Article
Neurosciences
Jessica A. Burket, Chelsea M. Young, Torrian L. Green, Andrew D. Benson, Stephen I. Deutsch
BRAIN RESEARCH BULLETIN
(2016)
Article
Neurosciences
Torrian L. Green, Jessica A. Burket, Stephen I. Deutsch
BRAIN RESEARCH BULLETIN
(2016)
Article
Clinical Neurology
Stephen I. Deutsch, Jessica A. Burket, Andrew D. Benson, Maria R. Urbano
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2016)
Article
Multidisciplinary Sciences
Frency Varghese, Jessica A. Burket, Andrew D. Benson, Stephen I. Deutsch, Christian W. Zemlin
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2016)
Review
Clinical Neurology
Jessica A. Burket, Stephen I. Deutsch
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2019)
Editorial Material
Clinical Neurology
Stephen I. Deutsch, Jessica A. Burket, Maria R. Urbano
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2019)
Article
Clinical Neurology
Jessica A. Burket, Jerrah C. Pickle, Allison M. Rusk, Bronson A. Haynes, Julia A. Sharp, Stephen Deutsch
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2020)
Review
Clinical Neurology
Stephen Deutsch, Jessica A. Burket
Summary: There is a growing expert consensus on prescribing and monitoring psychotropic medications for adults and older adults with intellectual disability (ID). However, there is limited empirical evidence to guide physicians in selecting specific categories of psychotropic medications for challenging behaviors. Challenges in applying diagnostic criteria and assigning psychiatric diagnoses to adults with ID lead to confusion surrounding medication selection. Long-term antipsychotic medication use is common for challenging behaviors, despite questionable efficacy, with some recommending short-term use for imminent dangerousness or threat to residential placements. Interdisciplinary treatment teams are essential for non-pharmacological plans and regular medication monitoring. Well-designed clinical trials are necessary for homogeneous samples, with a focus on safety and clinical outcomes. Innovative pharmacological strategies have been suggested to prevent adaptive function decline and improve cognition in adults with ID. Translational clinical trials addressing pathogenic mechanisms and challenging behaviors raise societal issues regarding protection of vulnerable populations and prioritization of therapeutic targets.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Review
Biochemistry & Molecular Biology
Stephen Deutsch, Zachary N. M. Luyo, Jessica A. Burket
Summary: Various ASD risk alleles can lead to impairment of NMDA receptor activation, highlighting the need for the development of specific and selective translational therapeutic NMDA receptor agonists to restore balance.
Article
Medicine, General & Internal
Stephen I. Deutsch, Jessica A. Burket
MEDICAL CLINICS OF NORTH AMERICA
(2023)
Article
Biology
Jessica A. Burket, Mona Matar, Arriyam Fesshaye, Jerrah C. Pickle, Richard A. Britten
Summary: Exposure to He particles can impact cognitive flexibility and social interaction in male rats, leading to deficits in executive functions and possibly affective behavior. These findings suggest that a single behavioral end point may not fully represent the cognitive deficits induced by space radiation.
RADIATION RESEARCH
(2021)
Review
Clinical Neurology
Jessica A. Burket, Maria R. Urbano, Stephen I. Deutsch
CLINICAL NEUROPHARMACOLOGY
(2017)
Review
Clinical Neurology
Stephen I. Deutsch, Jessica A. Burket, Andrew D. Benson, Maria R. Urbano
Article
Clinical Neurology
Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns
Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2024)